OCT 01, 2020 8:04 PM PDT

Antidepressants Treats Lazy Eye

WRITTEN BY: Nouran Amin

A study published in Current Biology revealed how a therapeutic used as an antidepressant and for managing pain could treat adult amblyopia, a vision disorder often referred to as the “lazy eye”. The therapeutic is subanesthetic ketamine which is known to evoke rapid and long-lasting effects for treating depression.

Learn more about adult amblyopia which is the result of the brain failing to process inputs from one eye versus the other.

"Our study, demonstrates how a single-dose of subanesthetic ketamine reactivates adult visual cortical plasticity and promotes functional recovery of visual acuity defects resulting from amblyopia," explained Xiangmin Xu, PhD, a professor of anatomy and neurobiology and director of the Center for Neural Circuit Mapping at the UCI School of Medicine.

The study showed how ketamine could control the nervous system and make structural changes in a process known as neural plasticity.

"Our research team showed that ketamine down-regulates NRG1 expression in PV inhibitory cells, resulting in sustained cortical disinhibition to enhance cortical plasticity in adult visual cortex," said Steven F. Grieco, PhD, a postdoctoral scholar in the Xu lab and lead author.

"Through this neural plasticity-based mechanism, ketamine mediated functional recovery from adult amblyopia." Xin Qiao, PhD, a postdoctoral staff in the Xu lab is a co-first author for the published paper.

The study confirmed that utilizing sustained treatments of ketamine reactivates adult cortical plasticity however, more research is needed.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
SEP 30, 2020
Cancer
Chemokines Could be the Key in Controlling Glioma Stem Cells
SEP 30, 2020
Chemokines Could be the Key in Controlling Glioma Stem Cells
The transformation of a healthy cell into a cancerous one often comes with a slew of cellular signaling changes.  T ...
OCT 23, 2020
Drug Discovery & Development
Common Asthmatic Treatments Increase Risk of Bone Fractures
OCT 23, 2020
Common Asthmatic Treatments Increase Risk of Bone Fractures
A study published in the journal Thorax found that taking steroid inhalers or tablets for asthma treatment to control fl ...
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
NOV 06, 2020
Drug Discovery & Development
Anti-depressant Shows Promise in Treating Childhood Cancer
NOV 06, 2020
Anti-depressant Shows Promise in Treating Childhood Cancer
Researchers from Sweden and the US have found that a commonly prescribed antidepressant may help stop the growth of a ca ...
NOV 18, 2020
Cancer
Could Targeting the Proteasome be Effective Against Cancer?
NOV 18, 2020
Could Targeting the Proteasome be Effective Against Cancer?
One of the trickiest things about anti-cancer drug design is targeting. Today, most drugs on the market target critical ...
Loading Comments...